Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C Minnema, Meletios A. Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj Merzoug, Elena Papachristou, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2023) 142 (Supplement 1): 539.

https://doi.org/10.1182/blood-2023-185811

Published: 2023

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C Minnema, Ashutosh D. Wechalekar, Elena Papachristou, Giorgos Psarros, Pieter Sonneveld, Stefan Schonland

Blood (2023) 142 (Supplement 1): 4779.

https://doi.org/10.1182/blood-2023-185861

Published: 2023

Journal Articles

Light Chain Amyloidosis Plasma Cells Show Specific Chromatin Accessibility and Transcriptome

Blood (2023) 142 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2023-185614

Published: 2023

Journal Articles

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Blood (2023) 142 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2023-190226

Published: 2023

Journal Articles

Daratumumab-Based Regimens Versus Cybord in Newly Diagnosed Patients with AL Amyloidosis and IIIb Cardiac Stage: A Matched Case-Control Study

Claudia Bellofiore, Marco Basset, Pietro Benvenuti, Mario Nuvolone, Andrea Foli, Martina Nanci, Gianluigi Guida, Andrea Attanasio, Giampaolo Merlini, Giovanni Palladini, Paolo Milani

Blood (2023) 142 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2023-184681

Published: 2023

Journal Articles

Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis

Vaishali Sanchorawala, Ashutosh D Wechalekar, Efstathios Kastritis, Giovanni Palladini, Stefan Schönland, Raymond Comenzo, Anita D'Souza, Jack Khouri, Victor Jimenez-Zepeda, Katherine Ingrid Sprinz, Heather Hao, Wenying Huang, Laura Governale Aubrey, Morie A. Gertz

Blood (2023) 142 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2023-174703

Published: 2023

Journal Articles

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Eyal Lebel, Vladimir Vainstein, Paolo Milani, Giovanni Palladini, Tamir Shragai, Noa Lavi, Hila Magen, Assayag Miri, Irit Avivi Mazza, Moshe E Gatt

Blood (2023) 142 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2023-173317

Published: 2023

Journal Articles

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini

Blood (2023) 142 (14): 1208–1218.

https://doi.org/10.1182/blood.2022019406

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Giovanni Palladini, Meletios-Athanasios Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C. Minnema, Ashutosh D. Wechalekar, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Stefan Schönland

Blood (2022) 140 (Supplement 1): 7294–7296.

https://doi.org/10.1182/blood-2022-169688

Published: 2022

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C. Minnema, Meletios-Athanasios Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj, Sreeja Varghese, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2022) 140 (Supplement 1): 1841–1843.

https://doi.org/10.1182/blood-2022-168757

Published: 2022

Journal Articles

Bone Marrow-Free Sequencing of M Protein Genes in Monoclonal Gammopathies

Alice Nevone, Giulia Mazzini, Paolo Milani, Silvia Mangiacavalli, Anna Melati, Giulia Scanavino, Maria Girelli, Serena Caminito, Marco Basset, Claudio Salvatore Cartia, Pietro Benvenuti, Martina Nanci, Claudia Bellofiore, Andrea Foli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini, Mario Nuvolone

Blood (2022) 140 (Supplement 1): 12431–12433.

https://doi.org/10.1182/blood-2022-168615

Published: 2022

Journal Articles

Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy

Paolo Milani, Claudia Bellofiore, Marco Basset, Andrea Foli, Pietro Benvenuti, Francesca Fabris, Martina Nanci, Mario Nuvolone, Giampaolo Merlini, Giovanni Palladini

Blood (2022) 140 (Supplement 1): 7172–7173.

https://doi.org/10.1182/blood-2022-169614

Published: 2022

Journal Articles

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival

Marco Basset, Paolo Milani, Andrea Foli, Mario Nuvolone, Pietro Benvenuti, Martina Nanci, Francesca Fabris, Claudia Bellofiore, Giampaolo Merlini, Giovanni Palladini

Blood (2022) 140 (18): 1964–1971.

https://doi.org/10.1182/blood.2022016348

Published: 2022

Includes: Supplemental data

Journal Articles

How I treat AL amyloidosis

Giovanni Palladini, Giampaolo Merlini

Blood (2022) 139 (19): 2918–2930.

https://doi.org/10.1182/blood.2020008737

Published: 2022

Journal Articles

Two-hit strategy for treating AL amyloidosis?

Giampaolo Merlini, Giovanni Palladini

Blood (2021) 138 (25): 2596–2598.

https://doi.org/10.1182/blood.2021013817

Published: 2021

Journal Articles

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Blood (2021) 138 (Supplement 1): 159.

https://doi.org/10.1182/blood-2021-146820

Published: 2021

Journal Articles

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Blood (2021) 138 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2021-149594

Published: 2021

Journal Articles

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efstathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Antoine Huart, Karim Belhadj, Alexandros Leonidakis, Kyriaki Manousou, Pieter Sonneveld, Giovanni Palladini

Blood (2021) 138 (Supplement 1): 2730.

https://doi.org/10.1182/blood-2021-152540

Published: 2021

Journal Articles

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Blood (2021) 138 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2021-149222

Published: 2021

NARROW

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Light Chain Amyloidosis Plasma Cells Show Specific Chromatin Accessibility and Transcriptome

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Daratumumab-Based Regimens Versus Cybord in Newly Diagnosed Patients with AL Amyloidosis and IIIb Cardiac Stage: A Matched Case-Control Study

Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Bone Marrow-Free Sequencing of M Protein Genes in Monoclonal Gammopathies

Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy

Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival

How I treat AL amyloidosis

Two-hit strategy for treating AL amyloidosis?

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only